Back to Browse Journals » Drug Design, Development and Therapy » Volume 4

ACAM2000™: The new smallpox vaccine for United States Strategic National Stockpile

Authors Aysegul Nalca, Elizabeth E Zumbrun

Published Date May 2010 Volume 2010:4 Pages 71—79

DOI http://dx.doi.org/10.2147/DDDT.S3687

Published 17 May 2010

Aysegul Nalca, Elizabeth E Zumbrun

Center for Aerobiological Sciences, US Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, MD, USA

Abstract: Smallpox was eradicated more than 30 years ago, but heightened concerns over bioterrorism have brought smallpox and smallpox vaccination back to the forefront. The previously licensed smallpox vaccine in the United States, Dryvax® (Wyeth Laboratories, Inc.), was highly effective, but the supply was insufficient to vaccinate the entire current US population. Additionally, Dryvax® had a questionable safety profile since it consisted of a pool of vaccinia virus strains with varying degrees of virulence, and was grown on the skin of calves, an outdated technique that poses an unnecessary risk of contamination. The US government has therefore recently supported development of an improved live vaccinia virus smallpox vaccine. This initiative has resulted in the development of ACAM2000™ (Acambis, Inc.™), a single plaque-purified vaccinia virus derivative of Dryvax®, aseptically propagated in cell culture. Preclinical and clinical trials reported in 2008 demonstrated that ACAM2000™ has comparable immunogenicity to that of Dryvax®, and causes a similar frequency of adverse events. Furthermore, like Dryvax®, ACAM2000™ vaccination has been shown by careful cardiac screening to result in an unexpectedly high rate of myocarditis and pericarditis. ACAM2000™ received US Food and Drug Administration (FDA) approval in August 2007, and replaced Dryvax® for all smallpox vaccinations in February 2008. Currently, over 200 million doses of ACAM2000™ have been produced for the US Strategic National Stockpile. This review of ACAM2000™ addresses the production, characterization, clinical trials, and adverse events associated with this new smallpox vaccine.
Keywords: smallpox, vaccinia, variola, vaccine, efficacy, safety

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Nanostructured polyurethane-poly-lactic- co-glycolic acid scaffolds increase bladder tissue regeneration: an in vivo study

Yao C, Hedrick M, Pareek G, Renzulli J, Haleblian G, Webster TJ

International Journal of Nanomedicine 2013, 8:3285-3296

Published Date: 28 August 2013

Amino acid management of Parkinson’s disease: a case study

Marty Hinz, Alvin Stein, Thomas Uncini

International Journal of General Medicine 2011, 4:165-174

Published Date: 28 February 2011

New approaches in the management of multiple sclerosis

Laurie J Barten, Douglas R Allington, Kendra A Procacci, et al

Drug Design, Development and Therapy 2010, 4:343-366

Published Date: 24 November 2010

Chimeric design, synthesis, and biological assays of a new nonpeptide insulin-mimetic vanadium compound to inhibit protein tyrosine phosphatase 1B

Thomas Scior, José Antonio Guevara-García, FJ Melendez, et al

Drug Design, Development and Therapy 2010, 4:231-242

Published Date: 23 September 2010

Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome

Son V Pham, Phuong-Chi T Pham, Phuong-Mai T Pham, et al.

Drug Design, Development and Therapy 2010, 4:203-220

Published Date: 6 September 2010

New anticoagulants for the prevention of venous thromboembolism

Cecilia Becattini, Alessandra Lignani, Giancarlo Agnelli

Drug Design, Development and Therapy 2010, 4:49-60

Published Date: 7 April 2010

Effects of selective serotonin reuptake inhibitors on motor neuron survival

Lily B Anderson, Phaedra B Anderson, Thea B Anderson, Amy Bishop, et al.

International Journal of General Medicine 2009, 2:109-115

Published Date: 28 May 2009

Bone resorption in incompletely impacted mandibular third molars and acute pericoronitis

Minoru Yamaoka, Yusuke Ono, Masahiro Takahashi, Ryosuke Doto, et al.

Clinical, Cosmetic and Investigational Dentistry 2009, 1:7-12

Published Date: 14 April 2009

Apoptotic and chemotherapeutic properties of iron(III)-salophene in an ovarian cancer animal model

Thilo S Lange, Carolyn McCourt, Rakesh K Singh, Kyu Kwang Kim, Ajay P Singh, et al

Drug Design, Development and Therapy 2009, 3:17-26

Published Date: 17 December 2008